TOKEN2049
8.9.2022 10:46:43 CEST | Business Wire | Press release
TOKEN2049, Asia’s premier crypto conference, announced the DJ line-up of AFTER 2049, the official closing event of this year’s September edition. Headlined by Istanbul-based DJ and producer Carlita, electronic icon DJ Tennis, and Moojo, Mo-Shi and Leon (Calamar Crew), AFTER 2049 will be taking place on Friday, 30 September as it takes over the rooftop of the city's most iconic building, Marina Bay Sands.
Occupying both the iconic observation deck that offers unparalleled, uninterrupted views of the Singapore skyline, and CÉ LA VI, one of Singapore’s most iconic nightlife institutions, AFTER 2049 will be hosted in tandem with the first practice round of the Formula 1 Singapore Grand Prix 2022. The exclusive event will feature exhilarating views of the night race at what’s set to be the Singapore Grand Prix race weekend’s largest party.
Raphael Strauch, Founder of TOKEN2049 said: “AFTER 2049 is our way of thanking our community, partners and speakers who’ve supported us from day one. We’re thrilled to be bringing some of the biggest names in electronic music, while showcasing some of the rising stars in the region. Coming on the back of what’s going to be Asia’s largest crypto event with over 5,000 attendees, AFTER 2049 is set to raise the bar for nightlife events in Singapore and the broader Asia Pacific region.”
A limited number of tickets for AFTER 2049 will be sold via Resident Advisor from 13 September onwards.
TOKEN2049 Singapore marks the conference’s Singapore debut which runs from 28 to 29 September ahead of the Singapore Grand Prix race weekend. Sponsors of AFTER 2049 include Asia’s one-stop gateway to Web 3.0 and one of the region’s leading providers of non-custodial staking services RockX; core blockchain infrastructure company Parity Technologies; leading blockchain and digital currency-focused venture capital firm Cypher Capital; one-stop, cross-chain aggregator for decentralised finance and metaverse products XY Finance; Asia-based full-stack proprietary venture capital firm Newman Capital; and Singapore-based crypto unicorn and digital assets financial services platform Matrixport.
Attendees will be able to hear from some of the industry’s leading entrepreneurs and thought leaders on all aspects of the broader crypto and Web3 arena. As part of Asia Crypto Week, TOKEN2049 attendees can expect to attend a full line-up of side events, conferences, networking events, workshops, and parties taking place throughout the week.
Additional sponsors for AFTER 2049 include leading South Korean game company Wemade; world’s largest cryptocurrency derivatives copy trade platform Bitget; the EOS Network Foundation which is building a coordinated future for the EOS Network through decentralization and community; digital asset exchange AAX; global online identity verification platform Trulioo; cryptocurrency and derivatives exchange OKX; decentralised and open-source protocol Syscoin; global digital assets exchange Zipmex; and collaborative Web3 credential infrastructure Galxe.
To purchase tickets for AFTER 2049, please visit: https://ra.co/events/1578263.
For more information and continued updates on TOKEN2049 Singapore, please visit: https://www.asia.token2049.com/.
About TOKEN2049:
TOKEN2049 is a premier Web3 event, organised annually in Singapore and London, where decision-makers in the global crypto ecosystem connect to exchange ideas, network, and shape the industry. TOKEN2049 is a global meeting place for entrepreneurs, institutions, industry insiders, investors, and those with a strong interest in the crypto and blockchain industry.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220908005086/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom